Screener
Medline, Inc. MDLN Proceeds From Issuance Initial Public Offering
Proceeds From Issuance Initial Public Offering at other companies
Other financials
Where this comes from
Reported directly by Medline, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The source filing: Medline, Inc.’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:51 PM EST
- Fiscal year
- FY2025
- Accession
- 0002046386-26-000009
| (in millions) | Year ended / December 31, 2025 | Year ended / December 31, 2024 | Year ended / December 31, 2023 |
|---|---|---|---|
| Other investing activities | — | (3) | (11) |
| Net cash used in investing activities | (474) | (1,493) | (312) |
| Cash flows from financing activities | |||
| Proceeds from issuance of Class A common stock in initial public offering, net of underwriting discounts and commissions | 7,048 | — | — |
| Purchase of Class A common stock and redemptions of Common Units from Pre-IPO owners | (1,970) | — | — |
| Payment for offering costs | (36) | — | — |
| Proceeds from long-term borrowings | 7,569 | 15,932 | — |
| Repayment for long-term borrowings | (11,661) | (15,995) | (77) |
Item 8 - Financial Statements and Supplementary Data
FAQ
- What is Medline, Inc.'s proceeds from issuance initial public offering?
- Medline, Inc. (MDLN) reported proceeds from issuance initial public offering of $1.76B in Q4 2025.
- What does proceeds from issuance initial public offering mean?
- Represents the total cash proceeds received by the company from the sale of common stock during its initial public offering. This metric reflects the primary capital infusion from public markets to support growth, debt reduction, or general corporate purposes.
Ask your AI about Medline, Inc.'s proceeds from issuance initial public offering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude